

DESCRIPTION


Species Reactivity	Mouse
Specificity	Detects mouse IGF-I in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant rat IGF-I is observed, 15% cross-reactivity with recombinant human IGF-I is observed, and less than 2% cross-reactivity with recombinant mouse IGF-II is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant mouse IGF-I G133-Ala102 Accession # Q8CAR0
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Mouse IGF-I (Catalog # 791-MG)
Immunohistochemistry	5-15 µg/mL	See Below
Neutralization	Measured by its ability to neutralize IGF-I-induced proliferation in the MCF-7 human breast cancer cell line. Karey, K. P. <i>et al.</i> (1988) <i>Cancer Research</i> 48:4083. The Neutralization Dose (ND ₅₀) is typically 0.2-1.0 µg/mL in the presence of 15 ng/mL Recombinant Mouse IGF-I.	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Mouse IGF-I is synthesized as two precursor isoforms with alternate N- and C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature mouse IGF-I shares 94% and 99% aa sequence identity with human and rat IGF-I, respectively (2), and exhibits cross-species activity. It shares 60% aa sequence identity with mature mouse IGF-II. Circulating IGF-I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4-7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF-I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I association with IGF binding proteins increases its plasma half-life and modulates its interactions with receptors (10).

References:

1. Philippou, A. *et al.* (2007) *In Vivo* **21**:45.
2. Bell, G.I. *et al.* (1986) *Nucleic Acids Res.* **14**:7873.
3. Guvakova, M.A. (2007) *Int. J. Biochem. Cell Biol.* **39**:890.
4. Clemmons, D.R. (2006) *Curr. Opin. Pharmacol.* **6**:620.
5. Bluher, S. *et al.* (2005) *Best Pract. Res. Clin. Endocrinol. Metab.* **19**:577.
6. Garcia-Segura, L.M. *et al.* (2006) *Neuroendocrinology* **84**:275.
7. Malemud, C.J. (2007) *Clin. Chim. Acta* **375**:10.
8. Samani, A.A. *et al.* (2007) *Endocrine Rev.* **28**:20.
9. LeRoith, D. and S. Yakar (2007) *Nat. Clin. Pract. Endocrinol. Metab.* **3**:302.
10. Denley, A. *et al.* (2005) *Cytokine Growth Factor Rev.* **16**:421.